ArticleNPJ Parkinson's disease2025
Subitem-level multi-scale assessment and machine learning for three-class cognitive status classification in Parkinson's disease.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with Parkinson's disease (PD) frequently develop cognitive impairments, and early accurate classification of cognitive status is critically important for clinical intervention. In this study, we leveraged data from the Parkinson's Progression Markers Initiative (PPMI) to develop a two-stage machine-learning framework that distinguishes among three cognitive states: PD with normal cognition (PD-NC), PD with mild cognitive impairment (PD-MCI), and PD dementia (PDD). Our approach combined SHapley Additive exPlanations (SHAP) for model interpretability with an ensemble of XGBoost and multilayer perceptron (MLP) classifiers, addressing class imbalance via the SMOTE-Tomek method. All model development and validation were conducted with a strict hold-out evaluation, with the test-set entirely excluded from feature selection, model training, and threshold optimization. Independent validation demonstrated strong and balanced classification performance across all cognitive subgroups, with particularly effective identification of cognitively impaired individuals requiring clinical attention. The area under the receiver operating characteristic curve (AUC) for three-class discrimination exceeded 0.85. Key predictors, including Montreal Cognitive Assessment (MoCA) scores and activities of daily living assessments, were validated as clinically meaningful by SHAP analysis. The proposed two-stage explainable model demonstrates strong and balanced classification performance across cognitive subgroups in PD. Its ability to identify people at high risk for dementia highlights its potential utility in clinical workflows, particularly as a scalable tool for early cognitive stratification and decision support in routine neurology practice. However, external validation on diverse real-world cohorts is warranted before clinical implementation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.